The emergence of multidrug-resistant enteric fever led to the use of ciprofloxacin as the mainstay of therapy. Furthermore, nalidixic acid-resistant Salmonella typhi (NARST) with decreased susceptibility to ciprofloxacin causing therapeutic failure emerged and became endemic (Threlfall & Ward, 2001) . Consequently, there have been several isolated reports, including from India, on ciprofloxacin resistance (Adachi et al., 2005; Capoor et al., 2006; Cooke et al., 2006; Joshi & Amarnath, 2006; Kownhar et al., 2007; Mohanty et al., 2006; Nair et al., 2006; Renuka et al., 2005; Saha et al., 2006) . Reports of cephalosporin resistance have also emerged (Saha et al., 1999; Marano et al., 1999) .
The index case of ciprofloxacin-resistant Salmonella enterica serovar Paratyphi A (S. Paratyphi A) from our hospital was detected in December 2004 in the blood culture of a 7-year-old boy with septicaemia and bilateral cellulitis of the lower limbs of 2 months duration. He was treated for staphylococcal cellulitis with several broad-spectrum antimicrobials, including fluoroquinolones, in another hospital. In our hospital, his blood for culture grew S. Paratyphi A on the third day that was resistant to ciprofloxacin (MIC5256 mg ml 21 ) and he was Table 2 shows the comparative MICs of ciprofloxacin, cefotaxime and cefepime for the isolates.
Over a 5-year period, it was noted that the median age for enteric fever decreased significantly. There was an increase of 3.8 % in patients requiring hospitalization. This can be attributed to a commensurate increase in the numbers of NARST and instances of ciprofloxacin-resistant enteric fever, with treatment failures and morbidity. Emergence of S. Paratyphi A (18 % compared with 2 %) as a significant cause of enteric fever is in agreement with previous studies (Mandal et al., 2004; Nair et al., 2006) . This is perhaps due to the reduction in S. Typhi isolation because of the typhoid-specific vaccination in this region. A sustained increased rate of isolation during summer and monsoon months implies that water conditions and sanitation remain the same or that a large number of carriers are present in the community (Gautam et al., 2002) .
Over a 5-year period, the numbers of NARST increased from 51 to 93 % and instances of ciprofloxacin-resistant enteric fever further increased from 0.6 to 15.2 %. The MIC 90 for ciprofloxacin increased from 0.125 mg ml 21 to 1 mg ml 21 .
Decreased therapeutic efficacy of quinolones is attributed to their widespread indiscriminate use in human and veterinary medicine (Capoor et al., 2006; Saha et al., 2006) . This is further corroborated by the fact that recent reports of ciprofloxacin resistance in enteric fever emerged from the Indian subcontinent, where NARST is endemic (Capoor et al., 2006; Joshi & Amarnath, 2006; Kownhar et al., 2007; Mohanty et al., 2006; Saha et al., 2006) . This is perhaps the consequence of their indiscriminate prescription owing to their oral administration, easy availability and affordability. Multidrug resistance (ACCO) decreased from 30 to 7 %. Re-emergence of sensitivity to chloramphenicol in the current study and recent studies (Gautam et al., 2002; Mandal et al., 2004 ) is a direct consequence of its restricted use in the last decade. The rise in MIC 90 for third-and fourth-generation cephalosporins from 0.063 mg ml 21 to 0.25 mg ml 21 warrants their cautious use. Although ceftriaxone is well-established, cefixime and cefepime appear promising. These agents are prohibitively expensive for routine use in developing nations (Saha et al., 2006) . Moreover, there is also a concern that their extensive use in the outpatient setting will select b-lactamases, as has been observed in the hospital setting.
Resistance to quinolones and, more recently, increase in MIC levels for third-and fourth-generation cephalosporins have varying geographical patterns and re-emphasize the importance of continued surveillance in revision of enteric fever protocols. Correspondence: Deepthi Nair (deepthinair2@gmail.com)
